Analysts Offer Insights on Healthcare Companies: Antares Pharma (NASDAQ: ATRS) and Alnylam Pharma (NASDAQ: ALNY)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (NASDAQ: ATRS) and Alnylam Pharma (NASDAQ: ALNY) with bullish sentiments.

Antares Pharma (NASDAQ: ATRS)

In a report issued on September 5, David Amsellem from Piper Jaffray reiterated a Buy rating on Antares Pharma (NASDAQ: ATRS), with a price target of $4. The company’s shares closed yesterday at $3.02, close to its 52-week high of $3.37.

According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -1.0% and a 45.5% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Amphastar Pharmaceuticals.

Antares Pharma has an analyst consensus of Strong Buy, with a price target consensus of $5.

Alnylam Pharma (NASDAQ: ALNY)

In a report released yesterday, Edward Tenthoff from Piper Jaffray reiterated a Buy rating on Alnylam Pharma (NASDAQ: ALNY), with a price target of $110. The company’s shares closed yesterday at $72.53.

According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of 7.5% and a 46.4% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Ionis Pharmaceuticals Inc, and Aevi Genomic Medicine Inc.

Currently, the analyst consensus on Alnylam Pharma is Strong Buy and the average price target is $98.27, representing a 35.5% upside.

In a report issued on August 24, Jefferies also reiterated a Buy rating on the stock with a $102 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.